PEG-SN38 Clinical Programs Continue in Metastatic Breast Cancer,
Other Solid Tumors
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that, in
light of evolving standards of care for the treatment of metastatic
colorectal cancer (mCRC), the Company will discontinue its PEG-SN38
(EZN-2208) clinical program in this disease, following conclusion of its
Phase II study. Enzon continues to enroll studies for the Company's
other PEG-SN38 programs, which include a soon-to-be fully enrolled Phase
II study in metastatic breast cancer, a Phase I study in pediatric
cancer, and a Phase I study in combination with Avastin®
(bevacizumab injection) in solid tumors.
"While we may evaluate PEG-SN38 in earlier lines of colorectal cancer
treatment in future clinical trials, at this time, resources associated
with such trials are better directed toward areas of study with
nearer-term commercial potential," said Richard Mulligan, Ph.D.,
Vice-Chairman of Enzon's Board of Directors. "We remain highly
encouraged by the promising activity and safety of PEG-SN38 in a number
of cancers, including metastatic breast cancer, and look forward to the
rapid execution of studies in areas in which the full benefit of
irinotecan cannot be realized due to toxicity."
About Enzon
Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the
research and development of innovative therapeutics for cancer patients
with high unmet medical needs. Enzon's drug-development programs utilize
two platforms — Customized PEGylation Linker Technology (Customized
Linker Technology®) and third-generation mRNA-targeting
agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon
currently has four compounds in clinical development and multiple novel
LNA targets in preclinical research. Enzon receives royalty revenues
from licensing arrangements with other companies related to sales of
products developed using its Customized Linker Technology. Further
information about Enzon and this press release can be found on the
Company's website at www.enzon.com.
Forward Looking Statements
There are forward-looking statements contained herein, which can be
identified by the use of forward-looking terminology such as the words
"believes," "expects," "may," "will," "should," "potential,"
"anticipates," "plans," or "intends" and similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, events or
developments to be materially different from the future results, events
or developments indicated in such forward-looking statements. Such
factors include but are not limited to the timing, success and cost of
clinical studies for Enzon's product candidates, the ability to obtain
regulatory approval of Enzon's product candidates, Enzon's ability to
obtain the funding necessary to develop its product candidates, market
acceptance of and demand for Enzon's product candidates, and the impact
of competitive products, pricing and technology. A more detailed
discussion of these and other factors that could affect results is
contained in Enzon's filings with the U.S. Securities and Exchange
Commission, including Enzon's most recent Annual Report on Form 10-K for
the year ended December 31, 2010 . These factors should be considered
carefully and readers are cautioned not to place undue reliance on such
forward-looking statements. No assurance can be given that the future
results covered by the forward-looking statements will be achieved. All
information in this press release is as of the date of this press
release and Enzon does not intend to update this information.
Argot Partners
Investors:
Andrea Rabney,
212-600-1902
andrea@argotpartners.com
or
Media:
Meghan
Feeks, 212-600-1902
meghan@argotpartners.com
Source: Enzon Pharmaceuticals, Inc.
News Provided by Acquire Media
